Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 12;16(8):e1008735.
doi: 10.1371/journal.ppat.1008735. eCollection 2020 Aug.

Convalescent serum therapy for COVID-19: A 19th century remedy for a 21st century disease

Daniel Montelongo-Jauregui  1 , Taissa Vila  1 , Ahmed S Sultan  1 , Mary Ann Jabra-Rizk  1   2
Affiliations

Convalescent serum therapy for COVID-19: A 19th century remedy for a 21st century disease

Daniel Montelongo-Jauregui et al. PLoS Pathog. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Notable historic uses of antibody therapy against infectious diseases.
COVID-19, coronavirus disease 2019; MERS, Middle East respiratory syndrome; SARS, severe acute respiratory syndrome.
Fig 2
Fig 2. Overview of the use and applications of CP therapy.
Virus-neutralizing antibodies in the plasma of a patient who recovered from COVID-19 can be administered prophylactically to prevent infection in vulnerable individuals and those with known exposure to the virus (Prophylaxis). Convalescent plasma can also be administered to infected individuals to improve the clinical outcome (Treatment). CP, convalescent plasma; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
See this image and copyright information in PMC

References

    1. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–74. Epub 2020/02/03. 10.1016/S0140-6736(20)30251-8 - DOI - PMC - PubMed
    1. Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int J Epidemiol. 2020. Epub 2020/02/23. 10.1093/ije/dyaa033 . - DOI - PMC - PubMed
    1. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181–92. Epub 2018/12/12. 10.1038/s41579-018-0118-9 - DOI - PMC - PubMed
    1. Fan Y, Zhao K, Shi ZL, Zhou P. Bat Coronaviruses in China. Viruses. 2019;11(3). Epub 2019/03/06. 10.3390/v11030210 - DOI - PMC - PubMed
    1. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19—Preliminary Report. N Engl J Med. 2020. Epub 2020/05/24. 10.1056/NEJMoa2007764 - DOI - PubMed

Publication types